Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 31

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 16G
Chunk 31
---
CORPORATE GOVERNANCE.

Companies with securities
listed on NASDAQ are required to comply with United States federal securities laws, including the Sarbanes-Oxley Act of 2002, as well
as certain NASDAQ rules and corporate governance requirements. As a foreign private issuer, however, we are entitled to follow our home
country practice in lieu of the NASDAQ corporate governance standards, subject to certain exceptions and except to the extent that such
exemptions would be contrary to United States federal securities laws. The United Kingdom laws and practices followed by the Company in
lieu of NASDAQ rules are described below:

  We do not follow NASDAQ’s requirement that the Board of Directors be comprised of a majority of                                            

  We do not follow NASDAQ’s requirements applicable to independent director oversight of director                                          
  nominations, which require that director nominees either be selected or recommended by independent directors. In accordance with United  
  Kingdom law and practice, our directors are nominated by the Nominations Committee, which is comprised of all of the directors of the    
  Company.                                                                                                                                 
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  We do not follow NASDAQ’s requirement that the compensation committee be comprised of Independent  

  We do not require that the compensation committee consider the specific factors affecting consultant independence                               

  We do not follow NASDAQ’s requirements that non-executive directors meet on a regular basis without      
  management present. Our Board of Directors may choose to meet in executive session at their discretion.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────

  We do not follow NASDAQ’s quorum requirements for stockholder meetings. In accordance with United                                        

  We do not follow NASDAQ’s requirements to seek shareholder approval                                                                           

ITEM 16H. MINE SAFETY DISCLOSURE.